Investigating why African American men have higher rates of aggressive prostate cancer
The primary role of low NCOA6 expression in the prostate cancer disparity among African American men
This study is looking into why prostate cancer tends to be more common and more severe in African American men than in European American men, focusing on a protein called NCOA6 that is often lower in cancer cells from African American patients, to see how this might lead to more aggressive cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10544740 on NIH RePORTER |
What this research studies
This research focuses on understanding the reasons behind the higher incidence and severity of prostate cancer in African American men compared to European American men. It examines the role of a protein called NCOA6, which is often found at lower levels in prostate cancer cells from African American patients. By analyzing tissue samples, the researchers aim to determine how low NCOA6 expression contributes to the overexpression of another protein, EGFR, which is linked to more aggressive cancer forms. The study will involve comparing protein levels in cancerous and normal prostate tissues from both groups to uncover potential biological mechanisms behind these disparities.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American men diagnosed with prostate cancer.
Not a fit: Patients who are not African American or those without a prostate cancer diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and targeted treatments for prostate cancer in African American men.
How similar studies have performed: Previous research has shown that understanding genetic and molecular differences can lead to significant advancements in cancer treatment, suggesting this approach has potential for success.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Xu, Jianming — Baylor College of Medicine
- Study coordinator: Xu, Jianming
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.